We’ve written a fair amount about the menace of illicit labs in China and elsewhere, producing potent and lethal synthetic opioids, like fentanyl and its analogs, often marketed over the darknet. Illicitly produced synthetic drugs now account for fully half the opioid overdose deaths in this country. Drug policy analyst Robert DuPont has warned us that “the global illegal market is switching from agricultural products to purely synthetic drugs,” and that this fact is driving the future of the epidemic.
But what we’d frankly not known was that some of these illicit labs abroad are actually operating so openly that a couple Bloomberg journalists could go visit the owner of two of them at his home in Wuhan and casually inform him, to his apparent surprise, that he’d been indicted last September as a drug kingpin in Gulfport, Miss. We’d also not realized that China would react to all this by expressing offense that the US had “unilaterally” indicted one of its nationals and by arguing that the defendant had not violated any Chinese law—notwithstanding that he allegedly exported 22 drugs, including four fentanyl analogs, into the US, where they are banned. Continue reading “News Roundup: May 24, 2018”→
eDarkTrends, an interdisciplinary academic group, monitors the introduction of new synthetic opioids into global illicit drug markets via “cryptomarkets” on the so-called darknet.
eDarkTrends noticed five new synthetic opioids being offered for sale during just a two-week stretch from March 20 to April 3, 2018.
Synthetic opioids—including fentanyl, its analogs, and still more exotic drugs like U47700 and its analogs—accounted for 46 percent of opioid overdose deaths, and 31 percent of all drug overdose deaths in 2016.
In Ohio, where eDarkTrends is based, fentanyl and related drugs accounted for 58.2 percent of all unintentional drug overdose deaths.
At one level, the federal government is working with unprecedented dedication to curb the opioid crisis. The House Energy and Commerce Committee has now advanced 57 opioid-related bills (expected to reach the full House in June) while at least two Senate committees are marking up successor legislation to the Comprehensive Addiction and Recovery Act of 2016. Yet yesterday, at a House hearing to reauthorize the Office of National Drug Control Policy, the Trump Administration declined an invitation (see 35:45) to send the acting director (or any other representative) to participate. A National Drug Control Strategy, due in February, has not yet been submitted. One member of theWhite House Commission on Combating Opioid Drug Addiction and the Opioid Crisis has, in retrospect, denounced its work as a “sham.” Appropriations remains insufficient to meet demands, and the future shape of Medicaid—which undergirds addiction treatment—remains a question mark. Meanwhile, Sen. Lindsay Graham (R-SC), The Hill reports, is working on another repeal-and-replace bill for the Affordable Care Act. Continue reading “News Roundup: May 18, 2018”→